Biospecimen Unit

摘要 生物质化股的目标是提供必要的基础设施，以 有希望获得最高质量的人类肿瘤标本来支持这项使命 儿科肿瘤细胞图谱中心(CPTCA)。我们现有的生物资源库 基础设施现代化，密密麻麻，并得到了我们机构的高度支持。我们的 在几个类似的大型多机构项目中的领导角色发生了变化 特殊儿童癌症的治疗方法和护理标准，并提供 进一步的证据表明，该结构已经到位，以确保CPTCA的成功。 我们将前瞻性地收集20名患者的肿瘤和血液样本，为期3天 主要的儿科癌症。我们提出了以下三个具体目标：1)收购， 用于CPTCA的儿童高级别胶质瘤生物标记物的制备和特征 检查从诊断到复发的关键基因组转变；2)获取， 儿科高危神经母细胞瘤生物标记物的处理和特征 CPTCA定义肿瘤演变和对化疗的克隆动态反应 靶向治疗；3)获取、处理和鉴定儿科高危B细胞 急性淋巴细胞白血病(VHR ALL)生物疫苗用于CPTCA的进化 通过标准疗法和CAR-T细胞免疫疗法治疗疾病。在完成时 为此，我们将向鉴定股提供高质量的生物检疫试剂 全面的多组学和现场分析，集成了高度注释的 临床、分子、病理和放射学数据库。

Abstract The objective of the Biospecimen Unit is to provide the necessary infrastructure to prospectively acquire the highest quality human tumor specimens to support the mission of the Center for Pediatric Tumor Cell Atlas (CPTCA). Our existing biorepository infrastructure is modern, stream-lined and highly supported by our institution. Our leadership role in several similar, large scale multi-institutional projects have changed the therapeutic approach and standard of care of specific pediatric cancers and provide further evidence that the structure is already in place to ensure the success of CPTCA. We will prospectively collect tumor and blood samples from twenty patients for three major pediatric cancers. We propose the following three specific aims: 1) To acquire, process and characterize pediatric high-grade glioma biospecimens for the CPTCA examining the critical genomic transitions from diagnosis to relapse; 2) To acquire, process and characterize pediatric high-risk neuroblastoma biospecimens for the CPTCA to define tumor evolution and the clonal dynamic response to chemotherapy and targeted therapy; 3) To acquire, process and characterize pediatric very high-risk B-cell acute lymphoblastic leukemia (VHR ALL) biospecimens for the CPTCA for the evolution of disease through standard therapy and CAR-T cell immunotherapy. At the completion of this aim, we will provide high quality biospecimens to the Characterization Unit for comprehensive multi-omic and in situ analyses integrated with a highly annotated clinical, molecular, pathologic and radiographic database.